AI in healthcare and the clinical laboratory: implement the workflow, not the hype

Start with the problem the patient and the team need solved

Healthcare does not need another impressive demonstration that leaves the work unchanged. It needs fewer missed problems, shorter avoidable delays, reliable results and enough professional attention for the cases that demand it. AI deserves a place when it helps deliver those outcomes. Buying it is not evidence that an organization has become innovative.

My recommendation is to combine executive accountability with frontline design and shared technical support, then expand in stages. Leaders set the purpose, funding and safety boundaries. The people doing the work help shape and test the process. Informatics, quality, privacy, procurement and finance connect the departments. Giving every department a tool at once is not the same as building an integrated system.

This is an implementation perspective informed by published research and biomedical diagnostics training. The studies below answer specific questions; none proves that every AI product improves care, or that one management structure works everywhere.

What AI can help with, and what it can make worse

AI is not a single intervention. An image classifier, a deterioration prediction model and a language model that drafts text have different failure modes. A rules-based calculation or validated autoverification rule is also not automatically AI. Leaders should ask exactly what the software does, what information it uses and which decision changes because of it.

Potential benefits include directing attention to suspicious images, organizing information, anticipating workload and reducing repetitive documentation. The corresponding risks include missed abnormalities, unnecessary alerts, fabricated statements, uneven performance between patient groups and extra review work. A polished narrative can conceal an incorrect number just as easily as it can explain a correct one.

A useful first question is whether a simpler change would solve the problem. A missing interface, unclear ownership or a poorly designed queue may need ordinary process improvement. AI layered over a broken handoff can make that handoff faster without making it safer.

What the stronger evidence actually shows

The Swedish MASAI randomized mammography trial is a concrete example of useful task redesign. Its 2023 safety analysis reported a 44.3% reduction in screen-reading workload with AI-supported reading. That measure describes reading work in that screening pathway, not a 44.3% reduction in staffing needs across radiology. [1]

The 2026 primary-outcome report strengthens the evidence: interval cancer rates were 1.55 versus 1.76 per 1,000 participants, meeting the trial’s non-inferiority criterion. Sensitivity was 80.5% versus 73.8%, with specificity of 98.5% in both groups. The confidence interval for the interval-cancer rate ratio included no difference; this should not be presented as a demonstrated reduction in interval cancers or mortality. It is evidence for a particular screening workflow, not validation of unrelated laboratory AI. [2]

The caution is equally concrete. Wong and colleagues externally evaluated a widely implemented sepsis model and reported an area under the receiver operating characteristic curve of 0.63, substantially below the developer’s reported performance. This measure describes discrimination between patients with and without the outcome; it is not a percentage of correct diagnoses. A familiar vendor and broad adoption did not establish adequate local performance. [3]

In the prospective TREWS sepsis cohort, timely clinician confirmation of an alert was associated with better outcomes. Because the study was observational, it cannot establish that the software alone caused the improvement; clinician response and differences between patients may contribute. [4]

Goh and colleagues randomized 50 physicians to conventional resources with or without access to a language model for clinical vignettes. Access did not significantly improve the primary diagnostic-reasoning outcome. This was a vignette study, not a patient-outcome trial, but it challenges a common purchasing assumption: better standalone model performance does not automatically make the human-plus-software workflow better. [5]

What earlier technology changes can teach us

Healthcare has faced this problem before. In a before-and-after study of barcode medication administration with an electronic medication administration record, Poon and colleagues found non-timing administration errors fell from 11.5% to 6.8%, a 41.4% relative reduction. Errors were reduced, not eliminated. This was a workflow intervention studied in a particular setting, not proof that buying a scanner alone creates the same result elsewhere. [6]

The NASSS framework was developed from research on why health technologies are adopted, abandoned or fail to spread. It directs attention to the condition, technology, value, users, organization, wider environment and their changes over time. It is an implementation framework, not a randomized comparison proving that top-down management beats bottom-up management. [7]

My practical inference is that the unit of implementation should be the whole workflow. The purchasing decision, data quality, training, handoffs, exception process and ongoing support belong in the same plan. A successful demonstration at one site is the beginning of the scaling question, not its answer.

Top down, bottom up or across the organization?

Use all three, with different responsibilities. Top-down leadership is needed to authorize resources, establish risk limits and resolve conflicts between departments. Bottom-up participation is needed to expose the realities that a business case misses: night-shift staffing, poor specimens, unusual results, interruptions and time spent resolving exceptions. Horizontal coordination is needed because the patient’s journey crosses systems and budgets.

I would not distribute implementation effort evenly across every department. Select a small number of workflows with clear owners, adequate data and measurable outcomes. Build reusable governance and integration standards centrally, while allowing local teams to test whether the process works in their environment. This recommendation is consistent with implementation research and risk-management guidance; it is not a claim that a universal rollout sequence has been experimentally proven. [7, 9]

• Executive sponsor: approve the problem, resources and benefit measures; remove barriers that local managers cannot control.
• Clinical or laboratory owner: define intended use, acceptable errors, review responsibilities and the authority to stop use.
• Frontline team: map real work, test exceptions and report unexpected behavior without being penalized for exposing defects.
• IT, informatics, privacy and security: control access, integration, data handling, logging, recovery and vendor changes.
• Quality and finance: assess safety and total cost together, including work transferred to other departments.

Choose pilots across the care pathway, without launching everywhere

The following are proposed pilot candidates, not claims of proven AssayIQ AI products or guaranteed outcomes. Start with one or two, depending on capacity. A lower-risk administrative task can help the organization learn, but success there does not validate a diagnostic system.

An executive dashboard should receive the same concise evidence from each pilot: the baseline problem, people affected, change tested, safety findings, total cost and the decision needed. Avoid ranking teams by how many AI tools they have adopted.

• Laboratory operations: evaluate workload forecasting or exception-queue support. Measure delayed specimens, false priorities, review minutes and turnaround-time distribution by shift.
• Imaging or pathology: evaluate a task-specific image aid within its authorized use. Measure missed findings, false positives, reader workload and downstream follow-up.
• Nursing and inpatient teams: assess documentation assistance or a carefully governed alert workflow. Measure correction time, missed information, alerts per shift and escalation completion.
• Pharmacy: consider a supervised inventory or operational review tool. Track stockouts, expiry waste and review burden; clinical recommendations require a separate safety assessment.
• Procurement and finance: test demand planning or invoice anomaly review. Verify suggested findings against source records and count false flags, not only potential savings.
• Patient access and administration: test scheduling or draft communication support. Check accessibility, language quality, inappropriate routing and whether delays move elsewhere.

The clinical laboratory has specific integration risks

An AI system that consumes laboratory data must understand what the result actually represents. Assay names alone are insufficient. Units, specimen type, instrument and method, reference intervals, flags, collection time, result status and corrected results can all change interpretation. A result below a reporting limit must not silently become zero. A canceled test must not look like a reassuring normal result.

Before connecting a laboratory information system to another application, build and test a data map with the receiving team. Include duplicate messages, delayed messages, downtime recovery and amended reports. Test whether a method or reagent change changes the input distribution. These are proposed local engineering checks, not evidence that any single interface standard guarantees safety.

For an image-based laboratory tool, evaluation should reflect the intended specimen types, abnormal findings and review process. Rare but important abnormalities deserve deliberate assessment. Overall agreement can hide failures in a small group. For predictive tools, check calibration, meaning whether predicted risks match observed risks, as well as sensitivity and false alerts at the actual operating threshold.

Keep deterministic calculations traceable. Linearity, comparison and extended measurement interval reports should preserve raw observations, units, dilution factors, acceptance criteria and reviewer decisions. If AI is used to draft an explanation, the calculations and conclusions still need independent checks. A plausible paragraph must never substitute for study evidence.

Regulation is part of the design, not the final checkbox

In the United States, 42 CFR 493.1253 distinguishes verification of unmodified FDA-cleared or approved test systems from establishment of performance specifications for modified or other applicable test systems. Required characteristics depend on that situation. Adding AI does not erase the laboratory’s applicable obligations. Equally, it would be incorrect to say that every administrative AI tool requires an assay validation study under this section. Intended use and the role in testing matter. [10]

FDA’s January 2025 lifecycle guidance for AI-enabled device software remains labeled draft on the guidance page reviewed for this article. It is a proposal, not a binding final requirement. Product-specific regulatory status and permitted use must be checked separately. A hospital pilot, vendor demonstration or strong journal paper does not itself authorize a new clinical use. [11]

DECIDE-AI provides reporting guidance for early clinical evaluation of AI decision support, including attention to human interaction and real clinical use. It can help teams ask better evaluation questions, but it is neither regulatory clearance nor a substitute for a local approval process. [8]

A staged implementation plan leaders can use

The sequence below is a practical recommendation, not a fixed regulatory timetable. High-risk clinical uses may require substantially more preparation and evaluation than an administrative pilot. Advance when the evidence supports the next stage, rather than because a calendar deadline has arrived.

• 1. Define and baseline: name one problem, intended users and affected patients. Measure current performance and record exclusions, safety limits and a non-AI alternative.
• 2. Assess and contract: review evidence for the exact product and use, data permissions, security, integration costs, update notices, audit access and exit arrangements.
• 3. Test locally: use representative, appropriately governed data. Separate development from evaluation data and avoid allowing information from the future to leak into predictions.
• 4. Run in shadow mode where appropriate: compare outputs with actual work without allowing unapproved outputs to direct care. Record failures and review burden.
• 5. Pilot with supervision: train staff on expected failures, define overrides and escalation, and retain an operational fallback. Use an appropriate comparator and independent outcome review where feasible.
• 6. Review and expand: assess safety, subgroup performance, workload and total cost. Reassess at each new site or materially different workflow.
• 7. Monitor and retire when necessary: track performance, inputs, incidents and software versions. Set thresholds for investigation, suspension and rollback before launch.

Protect the integration after go-live

A launch approval applies to a defined configuration. A new model version, interface change, assay method, patient population or use case may alter performance. Assign an owner to assess those changes and determine the testing required before continued use. Maintain a record of what version produced an output and what action followed.

For generative tools, limit access to approved information sources where appropriate and require checks against those sources. Restrict sensitive information to approved environments under the organization’s privacy and security arrangements. Define retention, access, secondary use and vendor training permissions explicitly. A generic instruction to be careful is not a data-handling policy.

NIST’s voluntary AI Risk Management Framework organizes risk work around governance, mapping, measurement and management. That is a useful structure for ongoing ownership; it is not certification that a product is safe. The practical deliverable should be a maintained risk register with named owners, evidence and unresolved decisions. [9]

What this means for medical laboratory professionals

The sensible workforce question is which tasks will change, which new risks appear and what expertise the service still needs. Published evidence from the studies discussed here does not establish a reliable number of future laboratory jobs lost or created. A workload reduction in mammography cannot be converted into a staffing forecast for chemistry, hematology or microbiology.

My expectation is that some repetitive preparation and sorting work will shrink while verification, exception handling, data stewardship and oversight become more visible. That is a professional judgment, not a guaranteed employment outcome. Employers may also pursue staffing reductions, so workforce planning should be explicit rather than hidden inside an innovation announcement.

A technologist who understands interference, specimen quality, analytical limitations and clinical context provides knowledge that an apparently normal model output may conceal. Staff need training in evaluating false positives and false negatives, recognizing data problems, challenging an output and documenting an override. They also need protected time to learn. Adding AI review to a full workload and calling it efficiency is poor accounting.

Retain practical competence and downtime capability. Rotate staff through appropriate independent review and exception work. Include experienced bench professionals in purchasing and validation discussions, and create development routes into quality, informatics and implementation roles. Management should own system defects; a missed escalation should prompt examination of interface design, staffing and training as well as individual actions.

How my ASU training shapes this view

I completed the Master of Science in Biomedical Diagnostics at Arizona State University in 2023. My coursework included Foundations of Biomedical Informatics Methods I, immunoassay and molecular diagnostic technology, Regulation of Medical Diagnostics, Health Economics, Policy and Payment Models, Biomedical Device Design, and Leadership in Health Care, alongside research and an applied project. ASU’s official program materials describe the wider diagnostic science, technology and business curriculum. My completed courses are drawn from my own academic record; current course names and requirements may differ. [12]

Those subjects provide a useful way to examine AI: informatics prompts questions about where data came from; diagnostic technology prompts questions about analytical limitations; regulation prompts questions about intended use and evidence; economics prompts questions about who pays and who benefits; leadership prompts questions about how people will adopt and sustain the change. These are my applications of that educational background, not a claim that ASU endorses this article or that the degree establishes AI product validation expertise.

In the assay report work behind AssayIQ, the practical priority is traceability from observations to calculations, interpretation and authorized review. The same discipline belongs in AI implementation. A clear report is valuable because a leader can examine the evidence and decide what to do, not simply because software produced it quickly.

Measure value without counting the same saving twice

A useful business case separates capacity released from cash actually saved. If a tool saves 20 minutes but those minutes are used for overdue quality work, the organization may gain valuable capacity without reducing payroll. If work is shifted to another team, the first department’s apparent saving may be an enterprise cost increase.

For illustration only, 300 hours of usable annual capacity valued at $50 per hour equals $15,000. If annual software and support cost $10,000 and first-year integration and training cost $8,000, that illustration has a negative $3,000 first-year balance before other benefits or costs. It does not demonstrate $15,000 in cash savings. Real decisions need observed local data, utilization assumptions and sensitivity analysis.

Report patient or service outcomes, process changes and balancing measures together. For a lab pilot, that might mean turnaround-time percentiles, incorrect priorities, amended results, review minutes, overtime and unresolved exceptions. Compare similar workloads and account for staffing or volume changes. Stop or redesign the pilot if apparent speed comes with worse quality. A credible decision to reject a poor tool is also a successful evaluation.

A useful first conversation with AssayIQ

Begin with one workflow that is expensive, delayed or difficult to control. AssayIQ can discuss a scoped review of the current process, the baseline measures, evidence needs, implementation responsibilities and the report leaders need to decide. Where specialist clinical, regulatory, cybersecurity or software engineering work is required, it should be identified and assigned within the agreed scope.

The aim is to make an investment decision that the organization can defend and a process that staff can operate. No blanket promise of autonomous diagnosis, guaranteed savings or regulatory approval is appropriate. Start with a defined problem, keep the evidence visible and expand only when the results justify it.